Pilot study on the mechanism of B cell chemotaxis of macrophage in ulcerative colitis

doi:10.3969/j.issn.1006-7795.2022.01.009

Abstract

Abstract: Objective To study the infiltration ratio of B cell and macrophage in the colon tissue during the progression of ulcerative colitis and explore the mechanism of chemotaxis between the two cells. Methods With the classic AOM/DSS mouse ulcerative colitis carcinogenesis model as the research object, the peripheral blood and colon tissues of mice at different disease stages were obtained. The proportion of immune cells was detected by flow cytometry, and the real-time PCR method and immunofluorescence method were used to detect chemokine monocyte chemoattractant protein-1 (MCP1/CCL2).Results The proportion of B cell and macrophage infiltration in colorectal tissues increased with the progress of ulcerative colitis-related colon cancer in mice. The infiltration of macrophages was significantly reduced if there was a lack of B cells. Further research found that B cell was one of the important sources of the chemokine CCL2 of macrophages. Conclusion During the progression of ulcerative colitis, B cells could chemoattract macrophages to colorectal tissues by up-regulating the expression of CCL2.

Key words: ulcerative colitis, B cell, macrophages, monocyte chemoattractant protein-1 (MCP1/CCL2)

CLC Number:

R574

Zhang Xinghua, Xing jie, Sun Can, Zhang Xi, Wang Yongjun. Pilot study on the mechanism of B cell chemotaxis of macrophage in ulcerative colitis[J]. Journal of Capital Medical University, 2022, 43(1): 42-46.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.01.009

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I1/42

References

[1] Tenesa A, Dunlop M G. New insights into the aetiology of colorectal cancer from genome-wide association studies[J]. Nat Rev Genet, 2009, 10(6): 353-358.
[2] Kellermayer R. Epigenetics and the developmental origins of inflammatory bowel diseases[J]. Can J Gastroenterol, 2012, 26(12): 909-915.
[3] Zhu S Y, Bing Y T, Wang X B, et al. CCL25/CCR9 interactions regulate the function of iNKT cells in oxazolone-induced colitis in mice[J]. Plos One, 2014, 9(6): e100167.
[4] Zeissig S, Kaser A, Dougan S K, et al. Role of NKT cells in the digestive system. III. Role of NKT cells in intestinal immunity[J]. Am J Physiol Gastrointest Liver Physiol, 2007, 293(6): G1101-G1105.
[5] Choi C H R, Bakir I A, Hart A L, et al. Clonal evolution of colorectal cancer in IBD[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 218-229.
[6] Farraye F A, Odze R D, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease[J]. Gastroenterology, 2010, 138(2): 738-745.
[7] Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies[J]. J Crohns Colitis, 2015, 9(11): 945-965.
[8] Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders[J]. J Crohns Colitis, 2017,11(6):649-670.
[9] Rubin D T, Ananthakrishnan A N, Siegel C A, et al. ACG Clinical Guideline: ulcerative colitis in adults[J]. Am J Gastroenterol,2019,114(3):384-413.
[10] Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer[J]. Cancer Microenviron,2011, 4(2): 141-154.
[11] Murray P J, Wynn T A. Protective and pathogenic functions of macrophage subsets[J]. Nat Rev Immunol, 2011, 11(11): 723-737.
[12] Popivanova B K, Kitamura K, Wu Y, et al. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis[J]. J Clin Invest, 2008, 118(2): 560-570.
[13] Matsumoto S, Hara T, Mitsuyama K, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model[J]. J Immunol, 2010, 184(3): 1543-1551.
[14] Sun M, He C, Cong Y, et al. Regulatory immune cells in regulation of intestinal inflammatory response to microbiota[J]. Mucosal Immunol,2015,8(5):969-978.
[15] Uzzan M, Colombel J F, Cerutti A, et al. B Cell-activating factor (BAFF)-targeted B cell therapies in inflammatory bowel diseases[J]. Dig Dis Sci,2016,61(12):3407-3424.
[16] Kanga K J W, Mendonca P, Soliman K F A, et al. Effect of diallyl trisulfide on TNF-α-induced CCL2/MCP-1 release in genetically different triple-negative breast cancer cells[J]. Anticancer Res,2021,41(12):5919-5933.
[17] McClellan J L, Davis J M, Steiner J L, et al. Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 303(10): G1087-G1095.
[18] Popivanova B K, Kostadinova F I, Furuichi K, et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice[J]. Cancer Res, 2009, 69(19): 7884-7892.
[19] Yoon S, Kang B W, Park S Y, et al. Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer[J]. J Cancer Res Clin Oncol, 2016, 142(8): 1775-1780.